Stay updated with breaking news from Simbec Research Limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.
A cannabinoid receptor, that has shown potential as an effective treatment for chemotherapy induced peripheral neuropathy (CIPN) has been given approval for a phase 1 clinical trial by the Medicines and Healthcare Products Regulatory Agency (MRHA) and The Wales Research Ethics Committee 2 (REC 2).
Investegate announcements from Oxford Cannabinoid, 2022 Final Results